The Food and Drug Administration’s Commissioner’s National Priority Voucher pilot program, announced last year, is facing scrutiny as some experts recommend a pause or even cancellation. The debate was highlighted on June 19 when stakeholders raised concerns about the program's transparency and broader policy implications.
Michael Abrams, managing partner at Numerof & Associates, said a pause would “force program designers and implementers to be more articulate . . . making everybody feel more comfortable with the program itself.” Abrams suggested that the initiative may have been implemented quickly to show results before President Donald Trump’s second term ends in January 2029.
Peter Pitts, former associate commissioner at the FDA and president of the Center for Medicine in the Public Interest, advocated for ending the program. “It can cease to exist,” he said. “It is entirely redundant relative to the pathways that already exist, and I don’t think that the opinions of a small group of executives inside the FDA should be able to trump the sophisticated decision-making process the centers already have in place.”
Launched by former FDA Commissioner Marty Makary in June 2025 to streamline review processes for products tied to U.S. national priorities such as unmet medical needs and public health issues, officials discussed its aims at a public session earlier this month. Since then, seven drugs have received approval through this expedited pathway—including Eli Lilly’s GLP-1 pill Foundayo—and 22 vouchers have been distributed overall for therapies addressing cancer, rare diseases, mental health conditions and other priority indications.
However, industry representatives from companies like Johnson & Johnson and Merck joined physician groups and patient advocates during a June 4 meeting in urging greater transparency around how candidates are selected for vouchers. Regulatory experts noted continued uncertainty regarding selection criteria—a sentiment echoed by Democratic representative Jake Auchincloss, who described it as “shrouded in secrecy” last month.
The CNPV program has also faced controversy following high-profile incidents such as Disc Medicines’ drug rejection and Sanofi’s request to revoke its own voucher after reported interference from former acting Center for Drug Evaluation and Research director Tracy Beth Høeg—an intervention confirmed this week by current acting CDER director Michael Davis. In response to these events, some experts are calling for reevaluation of how such programs fit within existing FDA infrastructure.
While biopharma companies see value in faster market access through expedited reviews—according to Graig Suvannavejh of Mizuho Securities—they remain cautious about implementation details: “Bigger picture, I think companies would be in favor of a pause to make sure we understand what’s happening at the FDA...especially in terms of transparency.”
The CNPV offers an unprecedented one- to two-month turnaround but introduces new oversight structures involving top agency officials. A staff manual guide published earlier this year clarified roles on its review council; however, Pitts warned against political influence: “The commissioner is a political appointee . . . any direct interference in the review process by a political appointee leads to bad places...”
With ongoing calls for clarity on both intent and execution—and with recent workforce reductions straining resources—the future direction of this pilot remains uncertain.
